Erik Penser Bank initiates coverage on Elicera Therapeutics

Elicera Therapeutics AB (publ) has entered into an agreement with Erik Penser Bank regarding coverage. The initial analysis can be read in Swedish here: https://assets.website-files.com/5e85ca7e8347401d65425175/6405c8aca24f2672ebe9ffc5_ELICERA20230306.pdf

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

Certified Advisor

Erik Penser Bank

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company’s share (ELIC) is traded on Nasdaq First North Growth Market.For more information, please visit www.elicera.com